Skip to Content

Our R&D in key therapeutic areas.

We are Scientists at heart. That means that we work every day to provide solutions in key therapeutic areas, bringing new treatments to market in the field of dermatology, as well as having a significant interest in pain relief medications.

Our R&D in key therapeutic areas

Our biologists and chemists apply the most advanced technologies to understand underlying disease mechanisms. With this knowledge, they design and synthesise safe and effective chemical formulas that provide healthcare professionals with a greater range of treatment options. Their efforts have resulted in medicines used by patients in over 70 countries, significantly improving the lives of millions of people worldwide.

Here are some of the key breakthrough medicines resulting from our Proprietary R&D:

  • Aceclofenac
  • Aclidinium
  • Almagate
  • Almotriptan
  • Ebastine
  • Cinitapride
  • Clebopride
  • Piketoprofen

We invested 12.9% of our net sales in R&D in 2016.

More than 270 of our professionals are dedicated to R&D.

We have 3 R&D Centres in Europe.

Almirall has over 270 qualified professionals working in R&D in 3 centres in Spain, Switzerland & Germany. We also count on the contributions of a group in the USA dedicated to clinical and regulatory activities.

R&D Centre in Sant Feliu de Llobregat (Barcelona, Spain).
Headquarters & flagship R&D centre.

We carry out most of our R&D activities at our facility in Sant Feliu de Llobregat (just outside Barcelona), which was opened in 2006. Our flagship R&D centre, with a surface area of over 27,500m2, is equipped with the most advanced technology and employs highly-qualified professionals who cover all disciplines involved in the Research & Development of a new drug. In addition to this centre, we also have a chemical plant in Sant Andreu de la Barca (also in the Barcelona area). It supplies the active ingredients needed for toxicological, pre-clinical & clinical studies.

Almirall Centre in Reinbek (Germany).

Acquired by us from Hermal in 2007, the centre is located on the outskirts of Hamburg and has a total surface area of 21,000m2. At this facility, our experts work on development programmes to find new formulations for the treatment of skin diseases. Over 60 years of work in this field rank it as a leading dermatology centre in Europe.

Almirall R&D site in Lugano (Switzerland): Polichem.

The company, with R&D site base in Lugano, was adquired in 2016.
Polichem's core business focuses on dermatology and dermocosmetics, gynaecology and respiratory disorders. It owns a broad portfolio of patents granted in many countries all over the world, including the USA, covering original formulations and pharmaceutical technologies applicable across a wide range of therapeutic areas. Following a ‘forward-looking vision', Polichem owns innovative patent-protected development projects in various medical fields with a particular focus on specific skin conditions.